Mark McKenna

Venture Partner at ARCH Venture Partners

Overview

Mark McKenna serves as Venture Partner at ARCH Venture Partners [6]. McKenna is Chairman and Chief Executive Officer of Mirador Therapeutics, a precision medicine company focused on immunology and inflammation [2][3]. Previously, McKenna held the position of Chairman and Chief Executive Officer of Prometheus Biosciences from 2019 to 2023 [10], a clinical stage biotechnology company acquired by Merck for $10.8 billion in June 2023 [2]. McKenna also serves as Chairman of the Board at Apogee Therapeutics [9], Board Member at NewAmsterdam Pharma Corporation [5] and Spyre Therapeutics [7], Member of the Board of Trustees at Arizona State University [4], and Senior Advisor at Fairmount Funds Management LLC [8]. McKenna holds an MBA in Management from Azusa Pacific University [12], a Bachelor of Science in Marketing from Arizona State University [13], and completed the Wharton Fellows Program [11].

Profile introduction
Source excerptLinkedIn [2]

Mark C. McKenna is Chairman and Chief Executive Officer of Mirador Therapeutics. Mirador Therapeutics is a next generation precision medicine company focused on immunology and inflammation. He previously served as Chairman and Chief Executive Officer of Prometheus Biosciences (Nasdaq: RXDX) from 2019-2023.  Prometheus Biosciences was a clinical stage biotechnology company which created the first precision therapeutics for immune-mediated diseases which was acquired by Merck for $10.8B in June of 2023.  The acquisition represented the largest M&A takeout of pre-phase 3 company. Mr. McKenna…

Career history

  1. Chairman and Chief Executive OfficerMar 2024 to presentMirador Therapeutics
  2. Member Board of TrusteesJun 2025 to presentArizona State University
  3. Board MemberJul 2024 to presentNewAmsterdam Pharma Corporation
  4. Venture PartnerFeb 2024 to presentARCH Venture Partners
  5. Board MemberFeb 2024 to presentSpyre Therapeutics
  6. Senior AdvisorOct 2023 to presentFairmount Funds Management LLC
  7. Chairman of the BoardAug 2023 to presentApogee Therapeutics
  8. Chairman and Chief Executive OfficerAug 2019 to Jul 2023Prometheus Biosciences, Inc.

Education

  1. Wharton Fellows Program2014 - 2017The Wharton School
  2. MBA, Management2004 - 2008Azusa Pacific University

This page shows public professional information only, each fact cited. Is this you? send a correction, or ask for removal within 24 hours, no questions asked.